Atlas Trials

Obinutuzumab in Combination With Ibrutinib in Treating Patients With Relapsed Mantle Cell Lymphoma

Clinical trial NCT02736617 · COMPLETED

Trial details

NCT number
NCT02736617
Sponsor
OHSU Knight Cancer Institute
Status
COMPLETED
Phase
Phase 2
Study type
INTERVENTIONAL
Recurrent Mantle Cell LymphomaRefractory Mantle Cell Lymphoma
Start date
2016-07-05
Primary completion
2021-06-02
Enrollment
10

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.